Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.69 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 5/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419878 | 0.87 | CYP19A1 (0.52) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL17199255 | 0.87 | CYP19A1 (0.52) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL17199186 | 0.86 | CYP19A1 (0.52) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL2425532 | 0.86 | CYP19A1 (0.52) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL2123821 | 0.85 | CYP19A1 (0.67) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL30943220 | 0.85 | CYP19A1 (0.67) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL2122743 | 0.84 | CYP19A1 (0.66) | CYP19A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL16087011 | 0.84 | CYP19A1 (0.66) | CYP19A1GRIK1GRIK2MAPTMEN1 | |
| SCHEMBL3660283 | 0.84 | L3MBTL1 (0.64) | CYP19A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL2900943 | 0.84 | CYP19A1 (0.65) | CYP19A1GRIK1GRIK2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049480-B1 | 2-ARYLINDOLE DERIVATIVES AS mPGES-1 INHIBITORS | ACRAF (IT) | 2013-10-30 | — | — | EP | disclosed |
| CN-101490000-B | 2-Arylindole derivatives as mPGEs-1 inhibitors | ACRAF | 2012-10-03 | — | — | CN | disclosed |
| US-8017644-B2 | 2-arylindole derivatives as nPGES-1 inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20090186922-A1 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2009-07-23 | — | — | US | disclosed |
| CN-101490000-A | 2-arylindole derivatives as NPGES-1 inhibitors | ACRAF (IT) | 2009-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186922-A1 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS | PTGES, NAT1, CSNK1G2 | CYP19A1 636/4885GRIK1 1260/4885GRIK2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.